Datapoint: Gilead Shores Up Breast Cancer Indication for Trodelvy

The FDA last week granted Gilead Sciences’ Trodelvy full approval for the treatment of triple-negative breast cancer (TNBC) — clearing the drug for use in TNBC patients who have received two or more prior treatments, with at least one treatment administered in a metastatic setting. Previously, the drug was approved for use in patients who had received at least two prior treatments in a metastatic setting. Trodelvy, which Gilead picked up via its $21 billion acquisition of Immunomedics, Inc. last October, currently holds preferred formulary placement for just 3% of all covered lives. It is not covered for 23% of all insured lives.

SOURCE: MMIT Analytics, as of 4/9/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today